InMed Pharmaceuticals annual ebitda
2021
2022
2023
InMed Pharmaceuticals EBITDA Growth & History (INM)
InMed Pharmaceuticals's calculated EBITDA was −$7.7M for fiscal 2023.
View full InMed Pharmaceuticals company overviewInMed Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-06-30 | −$7.7M | $10.7M | — |
| 2022 | 2022-06-30 | −$18.4M | −$8.3M | — |
| 2021 | 2021-06-30 | −$10.1M | — | — |
InMed Pharmaceuticals quarterly ebitda
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q1 2024 | 2023-09-30 | −$2.5M | $979,156 | — |
| Q4 2023 | 2023-06-30 | −$284,928 | $7.5M | — |
| Q3 2023 | 2023-03-31 | −$1.9M | $1.5M | — |
| Q2 2023 | 2022-12-31 | −$2.1M | $2.2M | — |
| Q1 2023 | 2022-09-30 | −$3.5M | −$518,069 | — |
| Q4 2022 | 2022-06-30 | −$7.8M | −$4.7M | — |
| Q3 2022 | 2022-03-31 | −$3.4M | −$1.2M | — |
| Q2 2022 | 2021-12-31 | −$4.2M | — | — |
| Q1 2022 | 2021-09-30 | −$2.9M | — | — |
| Q3 2021 | 2021-03-31 | −$3.1M | — | — |
| Q2 2021 | 2020-12-31 | −$2.2M | — | — |
InMed Pharmaceuticals ebitda trends
Across the available reported history, InMed Pharmaceuticals's ebitda increased from −$18.4M to −$7.7M, a change of $10.7M. The latest reported quarter, Q1 2024, shows −$2.5M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review InMed Pharmaceuticals filings at SEC.gov ↗